Structure of dystrophia myotonica protein kinase

Protein Science

Volumn 18, Issue 4, 2009, Pages 782-791

  Elkins, Jonathan M ^a   Amos, Ann ^a   Niesen, Frank H ^a   Pike, Ashley C W ^a   Fedorov, Oleg ^a   Knapp, Stefan ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Active sites; BIM; Bisindolylmaleimide; Crystallization; Crystallography; DMPK; Enzyme inhibitors; enzymes; Kinase; Myotonic dystrophy; Protein crystallization; Protein structures; Structure

Indexed keywords

BISINDOLYLMALEIMIDE; BISINDOLYLMALEIMIDE 8; MYOTONIC DYSTROPHY PROTEIN KINASE; RHO KINASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CRYSTALLIZATION; DIMERIZATION; MYOTONIC DYSTROPHY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN STRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; CRYSTALLOGRAPHY, X-RAY; HUMANS; INDOLES; MALEIMIDES; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN MULTIMERIZATION; PROTEIN-SERINE-THREONINE KINASES;

EID: 63449137654     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.82     Document Type: Article

References (41)

1. Ranum LPW, Day JW (2004) Myotonic dystrophy: RNA Pathogenesis Comes into Focus. Am J Hum Genet 74: 793-804.
2. Day JW, Ranum LPW (2005) RNA pathogenesis of the myotonic dystrophies. Neuromuscular Disord 15:5-16.
3. Wans ink DG, Wieringa B (2003) Transgenic mouse models for myotonic dystrophy type 1 (DMi), Cytogenet Genome Res 100:230-242.
4. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum LPW (2001) Myotonic Dystrophy Type 2 Caused by a CCTG Expansion in Intron 1 of ZNF9. Science 293:864-867.
5. Mankodi A, Logigian E, Callahan L, McClain C, White R, Henderson D, Krym M, Thornton CA (2000) Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289:1769-1773.
6. Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, Timmers AM, Hauswirth WW, Swanson MS (2003) A Muscleblind Knockout Model for Myotonic Dystrophy. Science 302:1978-1980.
7. n expansions associated with myotonic dystrophy. EMBO J 19: 4439-4448.
8. Fardaei M, Rogers MT, Thorpe HM, Larkin K, Hamshere MG, Harper PS, Brook JD (2002) Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DMi and DM2 cells. Hum Mol Genet 11:805-814.
9. Orengo JP, Chambon P, Metzger D, Mosier DR, Snipes GJ, Cooper TA (2008) Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. PNAS 105:2646-2651.
10. Guiraud-Dogan C, Huguet A, Gomes-Pereira M. Brisson E, Bassez G, Junien C, Gourdon G (2007) DM1 CTG expansions affect insulin receptor isoforms expression in various tissues of transgenic mice. Biochim Biophys Acta 1772:1183-1191.
11. Jansen G, Groenen PJTA, Bächner D, Jap PHK, Coerwinkel M, Oerlemans F, van den Broek W, Gohlsch B, Pette D, Plomp JJ, Molenaar PC, Nederhoff MGJ, van Echteld CJA, Dekker M. Berns A, Hameister H, Wieringa B (1996) Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice. Nat Genet 13:316-324.
12. Reddy S, Smith DBJ, Rich MM, Leferovich JM, Reilly F, Davis BM, Tran K, Rayburn H, Bronson R, Cros D, Balice-Gordon RJ, Housman D (1996) Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy. Nat Genet 13:325-335.
13. Berul CI, Maguire CT, Aronovitz M.I. Greenwood J, Miller C, Gehrmann J, Housman D, Mendelsohn ME, Reddy S (1999) DMPK dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model. J Clin Invest 103:R1-R7.
14. Llagostera E, Catalucci D, Marti L, Liesa M, Camps M, Ciaraldi TP, ondo R, Reddy S, Dillmann WH, Palacin M, Zorzano A, Ruiz-Lozano P, Gomis R, Kaliman P (2007) Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and muscle insulin action. PLo S ONE 2:e1134.
15. Mounsey JP, John JE, III, Helmke SM, Bush EW, Gilbert J, Roses AD, Perryman MB, Jones LR, Moorman JR (2000) Phospholemman is a substrate for myotonic dystrophy protein kinase. J Biol Chem 275:23362-23367.
16. Murányi A, Zhang R, Liu F, Hirano K, Ito M, Epstein HF, Hartshorne DJ (2001) Myotonic dystrophy protein kinase phosphoryiates the myosin phosphatase targetting subu- nit and inhibits myosin phosphatase activity. FEBS Lett 493:80-84.
17. Kaliman P, Catalucci D, Lam JT, Kondo R, Gutiérrez JCP, Reddy S, Palacín M, Zorzano A, Chien KR, Ruiz-Lozano P (2005) Myotonic dystrophy protein kinase phosphoryiates phospholamban and regulates calcium uptake in cardio-myocyte sarcoplasmic reticulum. J Biol Chem 280:8016- 8021,
18. Groenen, P.J.T.A., Wansink DG, Coerwinkel MM, van den Broek W, Jansen G, Wieringa B (2000) Constitutive and regulated modes of splicing produce six major myotonic dystrophy protein kinase (DMPK) isoforms with distinct properties. Hum Mol Genet 9:605-616.
19. Garcia P, Ucurum Z, Bucher R, Svergun DI, Huber T, Lustig A, Konarev PV, Marino M, Mayans O (2006) Molecular insights into the self-assembly mechanism of dystrophia myotonica kinase. FASEB J 20:1142-1151.
20. Tan I, Seow KT, Lim L, Leung T (2001) Intermolecular and intramolecular interactions regulate catalytic activity of myotonic dystrophy kinase-related cdc42-binding kinase α. Mol Cell Biol 21:2767-2778.
21. Doran JD, Liu X, Taslimi P, Saadat A, Fox T (2004) New insights into the structure-function relationships of Rho- associated kinase: a thermodynamic and hydrodynamic study of the dimer-to-monomer transition and its kinetic implications. Biochem J 384:255-262.
22. 1 reveals the mechanism for ligand selectivity. J Biol Chem 281:260-268.
23. Yamaguchi H, Kasa M, Amano M, Kaibuchi K, Hakoshima T (2006) Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil. Structure 14:589-600.
24. Wansink DG, van Herpen, REMA, Coerwinkel-Driessen MM, Groenen, PJTA, Hemmings BA, Wieringa B (2003) Alternative splicing controls myotonic dystrophy protein kinase structure, enzymatic activity, and subcellular localization. Mol Cell Biol 23:5489-5501.
25. Kannan N, Haste N, Taylor SS, Neuwald AF (2007) The hallmark of AGC kinase functional divergence is its C-terminal tail, a cis-acting regulatory module. PNAS 104: 1272-1277.
26. Narayana N, Cox S, Xuong, N-H, Ten Eyck LF, Taylor SS (1997) A binary complex of the catalytix subunit of cAMP-dependent protein kinase and adenosine further defines conformational flexibility. Structure 5:921-935.
27. Gold MG, Barford D, Komander D (2006) Lining the pockets of kinases and phosphatases. Curr Opin Struct Biol 16:693-701.
28. Zhao B, Lehr R. Smallwood AM. Ho TF', Maley K, Randall T, Head MS, Koretke KK, Schnackenberg CG (2007) Crystal structure of the kinase domain of serum and glucocorticoid-regulated kinase 1 in complex with AMP-PNP. Prot Sci 16:1-9.
29. Messerschmidt A, Macieira S, Velarde M, Bädeker M, Benda C, Jestel A, Brandsterter H, Neuefeind T, Blaesse M (2005) Crystal structure of the catalytic domain of human atypical protein kinase C-iota reveals interaction mode of phosphorylation site in turn motif. J Mol Biol 352:918-931.
30. Shimizu M, Wang W, Walch ET, Dunne PW, Epstein HF (2000) Rac-1 and Raf-1 kinases, components of distinct signaling pathways, activate myotonic dystrophy protein kinase. FEBS Lett 475:273-277.
31. Dvorsky R, Blumenstein L, Vetter IR, Ahmadian MR (2004) Structural insights into the interaction of ROCK1 with the switch regions of RhoA. J Biol Chem 279:7098- 7104.
32. Bush EW, Helmke SM, Birnbaum RA, Perryman MB (2000) Myotonic dystrophy protein kinase domains mediate localization, oligomerization, novel catalytic activity, and autoinhibition. Biochemistry 39:8480-8490.
33. Komander D, Garg R, Wan PTC, Ridley AJ, Barford D (2008) Mechanism of multi-site phosphorylation from a ROCK1:RhoE complex structure. EMBO J 27:3175-3185.
34. Komander D, Kular GS, ScÜttelkopf AW, Deak M, Pra- kash KRC, Bain J, Elliott M, Garrido-Franco M, Kozikowski AP, Alessi DR, van Aalten DMF (2004) Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1. Structure 12:215-226.
35. Fedorov O, Marsden B, Pogacic V, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S (2007) A systematic interaction map of validated kinase inhibitors with Ser/ Thr kinases. PNAS 104:20523-20528.
36. Leslie AGW (1999) Integration of macromolecular diffraction data. Acta Crystallogr. 055:1696-1702.
37. Collaborative Computational Project Number 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D50:760-763.
38. Storoni LC, McCoy AJ, Read RJ (2004) Likelihood- enhanced fast rotation functions. Acta Crystallogr D60: 432-438.
39. Emsley P, Cowtan K (2004) COOT: model-building tools for molecular graphics. Acta Crystallogr D6o:2126-2132.
40. Murshudov GN, Vagin AA, Lebedev A, Wilson KS, Dodson EJ (1999) Efficient anisotropic refinement of macro- molecular structures using FFT. Acta Crystallogr D55: 247-255.
41. Brown PH, Schuck P (2006) Macromolecular size-and- shape distributions by sedimentation velocity analytical ultracentrifugation. Biophys J 90:4651-4661.